Latest Commercial Execution News

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

HITIQ Limited has drawn down a $1 million loan from a major shareholder associate, with plans to convert the debt into convertible notes subject to shareholder approval. The initial tranche aims to bolster working capital amid ongoing capital market challenges.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Globe Metals & Mining’s 2026 Bankable Feasibility Study for the Kanyika Niobium Project in Malawi confirms robust economics, a 24-year mine life, and a strategic phased development approach.

Genetic Signatures is undertaking a major organisational restructure to cut costs by $5 million and sharpen its commercial focus, aiming to accelerate growth in its diagnostic product offerings.

RLF AgTech has raised $4.5 million through an institutional placement to accelerate its commercial rollout and meet rising demand amid global fertiliser shortages.

RLF AgTech has completed its restructuring phase and is now shifting gears towards aggressive commercial execution under new CEO Stuart Upton. The company outlined its growth strategy and financial results in a recent investor webinar, signalling a clear path to profitability.

Green360 Technologies has successfully raised $4.5 million to back the commercial rollout of its Eco-Clay low-carbon cement product, aiming for market entry in the first half of 2026.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.